Abstract
Gadoxetate disodium (Gd-EOB-DTPA), as a hepatocyte-specific MRI contrast agent, plays a key role in the early-stage diagnosis, differential diagnosis, and treatment evaluation of liver diseases. Gd-EOB-DTPA-enhanced MRI has been recommended as a first-line imaging diagnostic method for the diagnosis of liver lesions by clinical guidelines in many countries and regions. However, there is currently a lack of standardized management consensus to guide the clinical practice of Gd-EOB-DTPA-enhanced MRI examinations. Therefore, there is an urgent need to establish a scientifically based, full-process management protocol to improve image quality and professional standards and ensure the effectiveness of examinations. The "Expert Consensus on Standardized Management of Gadoxetate Disodium-Enhanced MRI Examinations (version 2026)" integrates the latest evidence-based data and clinical experience to standardize the entire process-from contrast agent storage management, pre-examination assessment and preparation, and operational coordination during the examination to post-examination observation guidance. In addition, it aims to enhance the professional competence and emergency response level of radiology medical personnel, thereby improving patient compliance, diminishing the incidence rate of adverse events, and providing a scientific and reliable clinical practice basis for the standardized implementation and technical promotion of Gd-EOB-DTPA-enhanced MRI examination in clinical practice.